Skip to main content
Toggle navigation
Menu
Overall search
Search ClinicalINFO
In affiliation with
HIV.gov
Search
Close
Main navigation
Home
About
Guidelines
Drug Database
Glossary
News
Resources
Contact Us
English
Toggle Dropdown
English
Español (Spanish)
Home
Search Results
Overall search
Search ClinicalINFO
Search Results
3201 – 3220
of
3979
Dolutegravir (Tivicay, DTG)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-integrase-inhibitors-dolutegravir-tivicay
Special Considerations for Antiretroviral Therapy Use in Adolescents With HIV
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/specific-considerations-antiretroviral-therapy-use-adolescents-hiv
Lactic Acidosis
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lactic-acidosis
Lamivudine
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lamivudine
Protease Inhibitors (PIs)
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/protease-inhibitors-pis
Atazanavir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/atazanavir
Tipranavir (Aptivus, TPV)
https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-tipranavir-aptivus
Special Populations: HIV-2 Infection
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-hiv-2-infection
Appendix B: Leadership
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/appendix-b
Appendices
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/appendices
Appendix B. Important Guideline Considerations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/appendix-important-considerations
Isosporiasis (Cystoisosporiasis)
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/isosporiasis
Emtricitabine (Emtriva, FTC)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nrtis-emtricitabine-emtriva
Entry and Attachment Inhibitors
https://clinicalinfo.hiv.gov/guidelines/perinatal/entry-and-attachment-inhibitors
Dolutegravir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/dolutegravir
Virologic Failure and Antiretroviral Options
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/virologic-failure-and-antiretroviral
Lopinavir/Ritonavir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lopinavirritonavir
Doravirine (Pifeltro, DOR)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nnrtis-doravirine-pifeltro
Adverse Effects of Antiretroviral Agents
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adverse-effects-antiretroviral-agents
Nephrotoxic Effects
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/nephrotoxic-effects
Pagination
First page
«
Previous page
‹
…
Page
157
Page
158
Page
159
Page
160
Current page
161
Page
162
Page
163
Page
164
Page
165
…
Next page
›
Last page
»